Cognitive deficits are a core feature of schizophrenia, account for much of the impaired
functioning associated with the disorder and are not responsive to existing treatments. In this …

Cannabidiol (CBD) is an abundant non‐psychoactive phytocannabinoid in cannabis
extracts which has high affinity on a series of receptors, including Type 1 cannabinoid …

Anecdotal evidence that cannabis preparations have medical benefits together with the
discovery of the psychotropic plant cannabinoid Δ9-tetrahydrocannabinol (THC) initiated …

Antiseizure drugs (ASDs) prevent the occurrence of seizures; there is no evidence that they
have disease-modifying properties. In the more than 160 years that orally administered …

Clinical studies indicate that cannabidiol (CBD), the primary nonaddictive component of
cannabis that interacts with the serotonin (5-HT) 1A receptor, may possess analgesic and …

Cannabidiol (CBD) is one of the cannabinoids with non-psychotropic action, extracted from
Cannabis sativa. CBD is a terpenophenol and it has received a great scientific interest …

Objective Add‐on cannabidiol (CBD) significantly reduced seizures associated with Dravet
syndrome (DS) in a randomized, double‐blind, placebo‐controlled trial: GWPCARE1 Part B …

SCN1A, encoding the alpha 1 subunit of the sodium channel, is associated with several
epilepsy syndromes and a range of other diseases. SCN1A represents the archetypal …

Summary Δ 9-tetrahydrocannabinol (THC) and its sibling, cannabidiol (CBD), are produced
by the same Cannabis plant and have similar chemical structures but differ dramatically in …

The phytocannabinoids of Cannabis sativa L. have, since ancient times, been proposed as a
pharmacological alternative for treating various central nervous system (CNS) disorders …